ClinicalTrials.gg
Not yet recruitingNCT06566859Updated Aug 22, 2024

Comparison of ESP Block and M-TAPA Block Efficiency in Postoperative Analgesia Management in Nephrectomy Cases

An observational study in Pain, Postoperative, sponsored by Başakşehir Çam & Sakura City Hospital. Not yet recruiting at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by Başakşehir Çam & Sakura City Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Pain, Postoperative by Başakşehir Çam & Sakura City Hospital — 5 open to participants now, 8 under way, none of them phase 3. Pain, Postoperative · Başakşehir Çam & Sakura City Hospital.

Started
2024
with 3 others
Observational
5 of 16
1 open now
Registered
8th of 16
by date

Among the 16 studies in Pain, Postoperative by Başakşehir Çam & Sakura City Hospital, this one is one of 4 that started in 2024, is one of 5 observational ones, and was the 8th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

5 of the 16 studies in Pain, Postoperative by Başakşehir Çam & Sakura City Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Pain, Postoperative by Başakşehir Çam & Sakura City Hospital, or all of them as a file.
02

Study summary

Relieving postoperative nephrectomy pain requires multimodal approaches. Peripheral blocks such as ESP block and M-TAPA block and multimodal analgesics reduce side effects by reducing the use of other analgesics. This study aimed to compare the effectiveness of erector spinae plane block (ESP block) and modified thoracoabdominal nerve blocking with perichondrial approach (M-TAPA block) in postoperative analgesia management in nephrectomy cases.

Read the detailed description

Relieving postoperative nephrectomy pain requires multimodal approaches. The most commonly used in the treatment of pain are nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and infiltration of local anesthetics. Due to the side effects of NSAIDs and opioids, the application of regional analgesia techniques can reduce complications while providing better analgesia quality. Peripheral blocks such as ESP block and M-TAPA block and multimodal analgesics reduce side effects by reducing the use of other analgesics. Pain is considered one of the most important factors affecting the quality of healing. Postoperative pain delays the postanesthesia care unit, hospital stay, early ambulation, increases resource utilization, and negatively affects patient satisfaction. If postoperative analgesia is provided, all these negativities will be eliminated. This study aimed to compare the effectiveness of erector spinae plane block (ESP block) and modified thoracoabdominal nerve blocking with perichondrial approach (M-TAPA block) in postoperative analgesia management in nephrectomy cases.

03

Conditions studied

  • Pain, Postoperative

Keywords

  • nerve block
  • pain management
  • postoperative period
  • postoperative complications
  • regional anesthesia
  • pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients aged 18 and over with ASA1-2 who underwent elective nephrectomy.

.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients aged 18 and over with ASA1-2 who underwent elective nephrectomy

Exclusion criteria

Exclusion Criteria:

  • ASA ≥3
  • >35 kg/ m²
  • Infection in the block area
  • Coagulation disorder,
  • Known allergy to local anesthetics
  • Pregnant
  • Patient with neuropathy
  • Patient without cooperation
  • Patient who refuses to participate in the study
  • Patients under 18 years of age
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • M-TAPA Block

    Patients who have standard anesthesia are randomized with the research randomizer application while under anesthesia and M-TAPA block is applied under ultrasound guidance in the preoperative period. For the block, 50 mg of 0.25% bupivacaine and 100 mg lidocaine are injected, totaling 20cc.

    Other: NRS 0. hour · Other: NRS 6. Hour · Other: NRS 12. Hour · Other: NRS 24. Hour

  • ESP Block

    Patients who have standard anesthesia are randomized with the research randomizer application while under anesthesia and ESP block is applied under ultrasound guidance in the preoperative period. For the block, 50 mg of 0.25% bupivacaine and 100 mg lidocaine are injected, totaling 20cc.

    Other: NRS 0. hour · Other: NRS 6. Hour · Other: NRS 12. Hour · Other: NRS 24. Hour

Interventions

  • OtherNRS 0. hour

    Numerical rating scala

  • OtherNRS 6. Hour

    Numerical rating scala

  • OtherNRS 12. Hour

    Numerical rating scala

  • OtherNRS 24. Hour

    Numerical rating scala

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Management

    The primary outcome of this study is to demonstrate that Modified Thoracoabdominal Nerves Block(M-TAPA) contributes sufficiently to multimodal analgesia in perioperative analgesia in nephrectomy surgery.This contribution will be evaluated with the NRS. NRS is a unidimensional scale in which 11 numbers (between 0 and 10) are used to measure pain intensity. The patient is asked to choose the number that best reflects the pain intensity, with 0 = no pain and 10 = worst (unbearable) pain.

    Time frame: 0.hour

  2. Postoperative Pain Management

    The primary outcome of this study is to demonstrate that Modified Thoracoabdominal Nerves Block(M-TAPA) contributes sufficiently to multimodal analgesia in perioperative analgesia in nephrectomy surgery.This contribution will be evaluated with the NRS. NRS is a unidimensional scale in which 11 numbers (between 0 and 10) are used to measure pain intensity. The patient is asked to choose the number that best reflects the pain intensity, with 0 = no pain and 10 = worst (unbearable) pain.

    Time frame: 6.hour

  3. Postoperative Pain Management

    The primary outcome of this study is to demonstrate that Modified Thoracoabdominal Nerves Block(M-TAPA) contributes sufficiently to multimodal analgesia in perioperative analgesia in nephrectomy surgery.This contribution will be evaluated with the NRS. NRS is a unidimensional scale in which 11 numbers (between 0 and 10) are used to measure pain intensity. The patient is asked to choose the number that best reflects the pain intensity, with 0 = no pain and 10 = worst (unbearable) pain.

    Time frame: 12.hour

  4. Postoperative Pain Management

    The primary outcome of this study is to demonstrate that Modified Thoracoabdominal Nerves Block(M-TAPA) contributes sufficiently to multimodal analgesia in perioperative analgesia in nephrectomy surgery.This contribution will be evaluated with the NRS. NRS is a unidimensional scale in which 11 numbers (between 0 and 10) are used to measure pain intensity. The patient is asked to choose the number that best reflects the pain intensity, with 0 = no pain and 10 = worst (unbearable) pain.

    Time frame: 24.hour

  5. Postoperative Pain Management

    Total amount of analgesic used in 24 hours

    Time frame: 24 hours

  6. Postoperative Pain Management

    Time of first additional analgesic requirement up to 24 hours

    Time frame: 24 hours

07

Study locations

1 site
  • BasaksehirCamSakuraH
    Istanbul, Turkey
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Feb 2025, 5 months later.

Of 392 non-industry observational studies under Pain, Postoperative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 5 months is below that.

Counting every sponsor, half of 396 studies reached it within 13 months; a quarter within 6 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2024
First posted
Aug 22, 2024
StartEst.
Sep 1, 2024
Primary completionEst.
Feb 1, 2025
CompletionEst.
Feb 1, 2025
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06566859
Responsible party
Hilal AKCA (MD, Başakşehir Çam & Sakura City Hospital) — Principal investigator
First posted
Aug 22, 2024
Start date
Sep 1, 2024 (estimated)
Primary completion
Feb 1, 2025 (estimated)
Completion
Feb 1, 2025 (estimated)
Last update
Aug 22, 2024

Study contacts

Hilal Akça
Contact
drhllbs@gmail.com
05548421509
Hilal Akça
principal investigator · BasaksehirCamSakuraH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion